Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645840 · ClinicalTrials.gov registry record · Phase 1
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00645840 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT00645840, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1 beta pathways will be associated with preserved insulin secretory capacity.
Interventions
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645840
The ClinicalTrials.gov registry entry for NCT00645840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anakinra is the first listed.
NCT00645840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645840 about?
NCT00645840 is a clinical study titled "Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes". The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in children with newly di...
What is the current status of trial NCT00645840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00645840?
The interventions under investigation include: Anakinra (DRUG).
Who is sponsoring clinical trial NCT00645840?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.